Edition:
India

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Capital Market

3.93USD
17 Sep 2019
Change (% chg)

-- (--)
Prev Close
$3.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,153
52-wk High
$12.32
52-wk Low
$2.79

Latest Key Developments (Source: Significant Developments)

Atyr Pharma Files For Mixed Shelf Of Up To $20 Million – SEC Filing
Wednesday, 22 May 2019 

May 22 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA INC FILES FOR MIXED SHELF OF UP TO $20 MILLION – SEC FILING.  Full Article

aTyr Pharma Qtrly Loss Per Share $0.18
Tuesday, 14 May 2019 

May 13 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES FIRST QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE.ATYR PHARMA INC - QTRLY LOSS PER SHARE $0.18.ATYR PHARMA INC - AS OF MARCH 31, 2019, ATYR HAD $43.0 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS..ATYR PHARMA - SUBSEQUENT TO QUARTER-END, CO RAISED $5 MILLION IN GROSS PROCEEDS THROUGH REGISTERED DIRECT INVESTMENT LED BY FEDERATED KAUFMANN SMALL CAP FUND.  Full Article

ATyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
Monday, 11 Mar 2019 

March 11 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES RESEARCH COLLABORATION WITH GLOBAL BIOTHERAPEUTICS LEADER CSL BEHRING.ATYR PHARMA INC - ATYR ELIGIBLE TO RECEIVE UP TO $17 MILLION IN POTENTIAL OPTION FEES.ATYR PHARMA INC - CSL BEHRING WILL PAY A TOTAL OF UP TO $4.25 MILLION PER SYNTHETASE PROGRAM.ATYR PHARMA - ATYR WILL GRANT CSL BEHRING OPTION TO NEGOTIATE LICENSES FOR WORLDWIDE RIGHTS TO EACH IND CANDIDATE THAT EMERGES FROM COLLABORATION.  Full Article

Atyr Pharma Appoints Jill Broadfoot As CFO
Tuesday, 31 Jul 2018 

July 31 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA APPOINTS JILL BROADFOOT AS CHIEF FINANCIAL OFFICER.ATYR PHARMA INC - JILL BROADFOOT HAS JOINED ATYR AS CHIEF FINANCIAL OFFICER.  Full Article

Atyr Pharma Inc Posts Qtrly Loss Of $0.36 Per Share
Monday, 14 May 2018 

May 14 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS, PROGRAM PRIORITIZATION AND CORPORATE RESTRUCTURING.CORPORATE RESTRUCTURING INCLUDES AN IMMEDIATE WORKFORCE REDUCTION OF APPROXIMATELY 30% AS WELL AS ADDITIONAL COST SAVING MEASURES.RESTRUCTURING PLAN TO STREAMLINE ITS OPERATIONS AS IT FOCUSES ITS DEVELOPMENT EFFORTS ON FURTHER CLINICAL ADVANCEMENT OF ATYR1923.ATYR PHARMA - NOT TO PROCEED WITH IND-ENABLING ACTIVITIES, INCLUDING GMP MANUFACTURING, FOR PANEL OF ANTIBODIES IDENTIFIED IN ORCA PROGRAM.QTRLY LOSS PER SHARE $0.36.Q1 EARNINGS PER SHARE VIEW $-0.36 -- THOMSON REUTERS I/B/E/S.  Full Article

Atyr Pharma Says On Dec 22, Co Entered Into Amendment To Loan And Security Agreement Dated As Of Nov 18, 2016
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Atyr Pharma Inc ::ATYR PHARMA SAYS ON DEC 22, CO ENTERED INTO AMENDMENT TO LOAN AND SECURITY AGREEMENT DATED AS OF NOV 18, 2016 - SEC FILING.ATYR PHARMA - AMENDMENT NOW REQUIRES FOR DRAW OF THIRD TRANCHE OF LOAN TO INCLUDE AUSTRALIA AS QUALIFYING GEOGRAPHY FOR INITIATION OF IMOD.FC TRIAL.  Full Article

aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - aTyr Pharma Inc ::aTyr Pharma announces third quarter 2017 operating results and provides corporate update.aTyr Pharma Inc - ‍expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into middle of 2019​.aTyr Pharma Inc qtrly ‍net loss per share, basic and diluted $0.43​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Atyr Pharma says ‍John Mendlein transitions from CEO to non-executive board member​
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Atyr Pharma Inc ::Atyr Pharma announces leadership transition.Atyr Pharma Inc - ‍John Mendlein transitions from CEO to non-executive board member​.Atyr Pharma Inc - ‍Sanjay Shukla appointed president and CEO​.  Full Article